# Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation

> **NCT06440850** · PHASE2 · RECRUITING · sponsor: **City of Hope Medical Center** · enrollment: 21 (estimated)

## Conditions studied

- Thyroid Gland Follicular Carcinoma
- Thyroid Gland Oncocytic Carcinoma
- Thyroid Gland Papillary Carcinoma

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **DRUG:** Cobimetinib
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Diagnostic Imaging
- **PROCEDURE:** I-131 Uptake Test
- **RADIATION:** Iodine I-131
- **PROCEDURE:** Magnetic Resonance Imaging
- **PROCEDURE:** Positron Emission Tomography
- **BIOLOGICAL:** Recombinant Thyrotropin Alfa
- **PROCEDURE:** Ultrasound Imaging
- **DRUG:** Vemurafenib

## Key facts

- **NCT ID:** NCT06440850
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-15
- **Primary completion:** 2026-11-22
- **Final completion:** 2026-11-22
- **Target enrollment:** 21 (ESTIMATED)
- **Last updated:** 2026-02-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06440850

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06440850, "Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06440850. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*